EHA: Adding Pirtobrutinib to Venetoclax-Rituximab ups progression-free survival in chronic lymphocytic leukemia

For patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL), adding pirtobrutinib to venetoclax-rituximab (PVR) yields improved progression-free endurance (PFS) compared to venetoclax-rituximab (VR), according to a survey presented astatine the yearly legislature of the European Hematology Association, held from June 11 to 14 successful Stockholm.